#United States #Immunotherapy #Madison, Wisconsin #Dr. Jerome Galon #Elephas Biosciences

Elephas Biosciences Expands Scientific Advisory Board

In a significant development for immunotherapy research, Elephas Biosciences Corporation has announced the addition of Dr. Jerome Galon to its Scientific Advisory Board (SAB). This strategic appointment reinforces Elephas's commitment to enhancing its innovative platform designed to predict responses to immunotherapy treatments.

About Elephas Biosciences

Elephas Biosciences is a private company headquartered in Madison, Wisconsin, that has pioneered an advanced technology aimed at improving cancer treatment outcomes. The firm has developed a unique platform that utilizes live tissue from tumor biopsies to provide insights into how cancer patients might respond to various immunotherapies. By monitoring how live tumor samples react in real time, the technology positions Elephas at the forefront of personalized cancer care.

Meet Dr. Jerome Galon

Dr. Galon, who is based in France, is a globally recognized leader in the field of oncology. With decades of experience, he is celebrated for his groundbreaking work in tumor immunology. Dr. Galon holds a prestigious title as Director of Research Exceptional Class at INSERM (French National Institute of Health and Medical Research) and co-founded the European Academy of Tumor Immunology (EATI). Previously, he served as the Chief Scientific Officer (CSO) at HalioDx, a company focused on immuno-oncology diagnostics.

His extensive background and involvement in advanced imaging techniques are expected to provide invaluable insights as Elephas seeks to enhance its commercialization strategy.

A Vision for Innovation

Dr. Galon expressed his enthusiasm about his new role by stating, "For decades, I've believed that science and clinical progress must be driven by technological advances and approaches. I am excited to support Elephas as they commercialize an exceptional technology that will impact how patients will be treated."

By integrating Dr. Galon’s expertise, Elephas aims to refine its predictive capabilities, ensuring that patients receive the most suitable treatments as early as possible.

The Scientific Advisory Board at Elephas

Dr. Galon joins a team of esteemed professionals within the SAB, including:

• - Pooja Advani, M.B.B.S., M.D., Medical Oncologist, Breast Cancer, Mayo Clinic
• - David Braun, M.D., Ph.D., Medical Oncologist, Kidney Cancer, Yale School of Medicine
• - Christian Capitini, M.D., Director, University of Wisconsin School of Medicine and Public Health
• - Kevin Eliceiri, Ph.D., Professor of Microscopy, Medical Imaging and AI, University of Wisconsin-Madison
• - Janis M. Taube, M.D., M.Sc., Pathologist, Melanoma, Johns Hopkins Medicine
• - Jacob Sands, M.D., Medical Oncologist, Small Cell Lung Cancer, Dana-Farber Cancer Institute
• - Alan Venook, M.D., Medical Oncologist, Gastrointestinal Oncology, UCSF Health

These individuals bring a wealth of knowledge and experience, further solidifying Elephas's dedication to advancing research and development in oncology.

Addressing the Oncology Crisis

With cancer being a leading cause of mortality worldwide and projections indicating that the number of cancer patients could triple by 2060, the necessity for innovative solutions is urgent. Despite an increase in available immunotherapy options, the reality remains that only a small fraction of patients achieve favorable responses. Elephas aims to address this critical gap by deploying its Live platform, which captures the native tumor microenvironment to assess real-time responses to immunotherapy.

Conclusion

As Elephas continues to progress with its groundbreaking technology, the company is committed to improving patient outcomes through personalized treatment strategies. Dr. Galon’s appointment to the advisory board is a pivotal step in achieving these goals, showcasing Elephas's commitment to innovation and excellence in the field of cancer treatment. For more information, visit their official website at www.elephas.com and follow them on LinkedIn.